Back to Research Hub
Amylyx Pharmaceuticals, Inc.
AMLX
$13.55+0.54 (+4.15%)
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
StreetsValue research for Amylyx Pharmaceuticals, Inc. (AMLX)
Members get the full report for Amylyx Pharmaceuticals, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.